PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Korean Journal of Ophthalmology10.3341/kjo.2016.01252017315424Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical ExperienceAbdullah Ozkaya, Zeynep Alkin, Mesut Togac, Sibel Ahmet, Irfan Perente, Muhittin Taskapilihttps://synapse.koreamed.org/pdf/10.3341/kjo.2016.0125, https://synapse.koreamed.org/DOIx.php?id=10.3341/kjo.2016.0125, https://synapse.koreamed.org/DOIx.php?id=10.3341/kjo.2016.0125
Clinical Ophthalmology10.2147/opth.s1468420101271Initial clinical experience of ranibizumab therapy for neovascular age-related macular degenerationTryfon Rotsos, patelhttps://www.dovepress.com/getfile.php?fileID=8078
Journal of Clinical Medicine10.3390/jcm10122666202110122666Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month OutcomesChristof Haensli, Isabel B. Pfister, Justus G. Garweghttps://www.mdpi.com/2077-0383/10/12/2666/pdf
Clinical Ophthalmology10.2147/opth.s102592010913Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases Vemalahttps://www.dovepress.com/getfile.php?fileID=7280
Clinical Ophthalmology10.2147/opth.s4938520131849Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS studyIvo Abraham, Rakic, Anita Leys, Brie, Denhaerynck, Pacheco, Vancayzeele, Hermans, Karen MacDonaldhttps://www.dovepress.com/getfile.php?fileID=17521
Clinical Ophthalmology10.2147/opth.s10105020161047Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-upNadezhda Cvetkova, Kristina Hoelldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Maerkerhttps://www.dovepress.com/getfile.php?fileID=30777
Clinical Ophthalmology10.2147/opth.s2183782019Volume 132461-2467<p>Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)</p>Faye Horner, Peck Lin Lip, Hannah Clark, Randhir Chavan, Ambreen Sarmad, Bushra Mushtaqhttps://www.dovepress.com/getfile.php?fileID=54670, https://www.dovepress.com/getfile.php?fileID=54670
Ophthalmology10.1016/j.ophtha.2016.05.05420171243e31-e32Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)Mark C. Gillies, Vincent Daien, Vuong Nguyen, Daniel Barthelmeshttps://api.elsevier.com/content/article/PII:S0161642016305152?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0161642016305152?httpAccept=text/xml
Clinical Ophthalmology10.2147/opth.s2691622021Volume 15279-287Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular DegenerationMuhammad Raza Cheema, Joanna DaCosta, James Talkshttps://www.dovepress.com/getfile.php?fileID=65853, https://www.dovepress.com/getfile.php?fileID=65853
Graefe's Archive for Clinical and Experimental Ophthalmology10.1007/s00417-014-2799-8201425381217-1225Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomesMeidong Zhu, Jamie K. Chew, Geoffrey K. Broadhead, Kehui Luo, Nichole Joachim, Thomas Hong, Adil Syed, Andrew A. Changhttp://link.springer.com/content/pdf/10.1007/s00417-014-2799-8.pdf, http://link.springer.com/article/10.1007/s00417-014-2799-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00417-014-2799-8